Publications

(Displaying in Reverse Chronological Order)

2206
Agrawal S, Kaur KJ, Singh I, Bhade S R, Kaul CL and Panchagnula R. Minimum sample size and sampling time requirements for assessment of rifampicin bioequivalence from FDC formulations International Journal of Tuberculosis and Lung Disease 2005, 9, 1273-1280.
2207
Agrawal S, Kaur, KJ, Singh I, Bhade SR, Kaul CL and Panchagnula R. Determination of rifampicin bioequivalence in a three-drug FDC by WHO and indian protocols: effect of sampling schedule and size International Journal of Tuberculosis and Lung Disease 2005, 9, 75-80.
2208
Agrawal V, Paul MK and Mukhopadhyay AK. 6-Mercaptopurine and daunorubicin double drug liposome- Preparation, drug-drug interaction and characterization Journal of Liposome Research 2005, 15, 141-155.
2209
Ahmed M, Khanna S and Bharatam PV. Importance of Sulfoxidation in Rapid Racemisation of Glitazones Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry 2005, 44B, 600-606.
2210
Arun KHS, Kaul CL and Ramarao P. AT1 receptors and L-type calcium channels: functional coupling in supersensitivity to angiotensin II in diabetic rats Cardiovascular Research 2005, 65, 374-386.
2211
Ashokraj Y, Gunjan K, Kaul CL and Panchagnula R. Quality control of anti-tuberculosis fixed dose combination formulations in global market: Part-II (Accelerated stability studies) International Journal of Tuberculosis and Lung Disease 2005, 9, 1266-1272.
2212
Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MVS, Kaul CL and Panchagnula R. Establishment of a reference formulation for bioequivalence assessment of rifampicin-containing FDCs: an essential step towards improving tuberculosis treatment International Journal of Tuberculosis and Lung Disease 2005, 9, 791-796.
2213
Ashokraj Y, Singh I, Kaur KJ, Kohli G, Bhade SR, Varma MVS, Kaul CL and Panchagnula R. Plasma pooling: utility in expediting bioequivalence assessment of rifampicin-containing fixed-dose combinations International Journal of Tuberculosis and Lung Disease 2005, 9, 697-699.
2214
Bala I, Bhardwaj V, Hariharan S, Sitterberg J, Bakowsky U and Ravi Kumar MNV. Design of Biodegradable Nanoparticles: A Novel Approach to Encapsulate Poorly Soluble Phytochemical Ellagic acid Nanotechnology 2005, 16, 2819-2822.
2215
2216
Bharadwaj V, Hariharan S, Bala I, Lamprecht A, Kumar N, Panchagnula R and Ravi Kumar MNV. Pharmaceutical aspects of polymeric nanoparticles for oral delivery Journal of Biomedical Nanotechnology 2005, 1, 235-258.
2217
Bharatam PV, Patel DS and Iqbal P. Pharmacophoric features of biguanidienes: An Electronic Structure Study Journal of Medicinal Chemistry 2005, 48, 7615-7622.
2218
Bharate SB, Chauthe SK, Bhutani KK and Singh IP. An efficient two-step synthesis of jensenone isolated from Eucalyptus jensenii Synthesis of analogues and evaluation as antioxidants Australian Journal of Chemistry 2005, 58, 551-555.
2219
Bhutani H, Singh S and Jindal KC. Drug-drug interaction studies on first-line anti-tuberculosis drugs Pharmaceutical Development and Technology 2005, 10, 517-524.
2220
Bhutani H, Singh S, Jindal KC and Chakraborti AK. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs Journal of Pharmaceutical and Biomedical Analysis 2005, 39, 892-899.
2221
Chawla G and Bansal AK. Effect of processing on celecoxib and its solvates Pharmaceutical Development and Technology 2005, 9, 419-433.
2222
Dhanikula AB and Panchagnula R. Preparation and characterization of water-soluble prodrug, liposomes and micelles of paclitaxel Current Drug Delivery 2005, 2, 75-91.
2223
2224
Dunge A, Sharda N, Singh B and Singh S. Establishment of inherent stability of stavudine and development of a validated stability-indicating HPLC assay method Journal of Pharmaceutical and Biomedical Analysis 2005, 37, 1115-1119.
2225
Dunge A, Sharda N, Singh B and Singh S. Validated specific HPLC method for determination of zidovudine during stability studies Journal of Pharmaceutical and Biomedical Analysis 2005, 37, 1109-1114.
2226
Garg S, Vermani K, Garg A, Anderson RA, Rencher WB and Zaneveld LJ. Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent Pharmaceutical Research 2005, 22, 584-595.
2227
2228
Garg SK, Kumar R and Chakraborti AK. Zinc perchlorate hexahydrate catalysed conjugate addition of thiols to -unsaturated ketones Synlett 2005, 2005, 1370-1374.
2229
Gaur A, Bhutani H, Mariappan TT and Singh S. Behaviour of marketed packaged formulations under accelerated conditions of temperature and humidity in the absence and the presence of light Indian Journal of Pharmaceutical Sciences 2005, 67, 438-443.
2230
Gaur A, Mariappan TT, Bhutani H and Singh S. Variable air velocity within stability chambers: A possible cause of out-of-trend stability results Pharmaceutical Technology 2005, 29, 44-49.
2231
Ghatta S, Srinivasan K, Kaul CL, Ramarao P. A study on alpha-adrenoceptor mediated contractile responses of high fat diet fed rat thoracic aorta Die Pharmazie 2005, 60, 142-146.
2232
2233
Gupta P and Bansal AK. Devitrification of amorphous celecoxib AAPS PharmSciTech 2005, 6, E223-E230..
2234
Gupta P and Bansal AK. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems PDA Journal of Pharmaceutical Science and Technology 2005, 59, 346-354.
2235
Gupta P and Bansal AK. Molecular interactions in celecoxib-PVP-meglumine amorphous system Journal of Pharmacy and Pharmacology 2005, 57, 303-310.
2236
Gupta P and Bansal AK. Spray drying for generation of a ternary amorphous system of celecoxib, PVP and meglumine Pharmaceutical Development and Technology 2005, 10, 257-267.
2237
2238
2239
Gupta P, Thilagavathi R, Chakraborti AK and Bansal AK. Differential molecular interactions between the crystalline and the amorphous phases of celecoxib Journal of Pharmacy and Pharmacology 2005, 57, 1271-1278.
2240
Gupta P, Thilagavathi R, Chakraborti AK and Bansal AK. Role of molecular interaction in stability of celecoxib-PVP amorphous systems Molecular Pharmaceutics 2005, 2, 384-391.
2241
Haas J, Ravi Kumar MNV, Borchardt G, Bakowsky U and Lehr CM. Preparation and characterisation of chitosan and trimethyl-chitosan modified PCL nanoparticles as potential DNA carriers AAPS PharmSciTech 2005, 6, E22-E30..
2242
Jadhav AN and Bhutani KK. Ayurveda and gynecological disorders Journal of Ethnopharmacology 2005, 97, 151-159.
2243
2244
Jain JP, Waknis V, Modi S, Ravi Kumar MNV and Kumar N. Trapping EPR for polymer drug conjugate delivery Drug Delivery Technology 2005, 5, 65-69.
2245
Jain M, Khan SI, Tekwani BL, Jacob MR, Singh S, Singh PP and Jain R. Synthesis, antimalarial, antileishmanial, and antimicrobial activities of some 8-quinolinamine analogues Bioorganic & Medicinal Chemistry 2005, 13, 4458-4466.
2246
2247
Kamble AL, Soni P and Banerjee UC. Biocatalytic synthesis of S(-)-1-(1'-naphthyl) ethanol by a novel isolate of Candida viswanathii Journal of Molecular Catalysis B: Enzymatic 2005, 35, 6-1.
2248
2249
Kaur D, Sharma P and Bharatam PV. Amide resonance in thio- and seleno- Carbamates: A Theoretical Study Journal of Molecular Structure: THEOCHEM 2005, 757, 149-153.
2250
Kaur N, Lu X, Gershengorn MC and Jain R. Thyrotropin-releasing hormone (TRH) analogues that exhibit selectivity to TRH receptor subtype 2 Journal of Medicinal Chemistry 2005, 48, 6162-6165.